Ocular Therapeutix Inc. [OCUL] Unchanged to Outperform at JMP Securities
JMP Securities maintained its Ocular Therapeutix Inc. [NASDAQ:OCUL] rating to the equivalent of Outperform but changed the price target to $30 from $20, in a research note dated December 30, 2020. That figure represents around a 49.40% premium from where the company’s shares closed on Tuesday. Other analysts also revised their coverage, with H.C. Wainwright’s […]
Ocular Therapeutix Inc. [OCUL] Downgraded to Neutral at H.C. Wainwright
H.C. Wainwright took its Ocular Therapeutix Inc. [OCUL] rating to the equivalent of Neutral from Buy, in a research note dated December 28, 2020. Some new analysts also started their coverage, with Berenberg’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid December. Meanwhile, Raymond James had […]
